Ramucirumab for treating advanced gastric cancer or gastro–oesophageal junction adenocarcinoma previously treated with chemotherapy

  • Technology appraisal guidance
  • TA378
  • Published: 
Download guidance (PDF)

7 Sources of evidence considered by the Committee

A. The Evidence Review Group (ERG) report for this appraisal was prepared by Kleijnen Systematic Reviews Ltd:

  • Riemsma R, Al M, Büyükkaramikli N et al. Ramucirumab for treating advanced gastric cancer or gastro‑oesophageal junction adenocarcinoma previously treated with chemotherapy, July 2015

B. The following organisations accepted the invitation to participate in this appraisal as consultees and commentators. They were invited to comment on the draft scope, the ERG report and the appraisal consultation document (ACD). Organisations listed in I were also invited to make written submissions. Organisations listed in II and III had the opportunity to make written submissions. Organisations listed in I, II and III also have the opportunity to appeal against the final appraisal determination.

I. Company:

  • Eli Lilly and Company

II. Professional/expert and patient/carer groups:

  • Independent Cancer Patients' Voice

  • Association of Cancer Physicians

  • Cancer Research UK

  • Oesophageal Patients Association

  • Royal College of Nursing

  • Royal College of Physicians

  • Royal College of Radiologists

III. Other consultees:

  • Department of Health

  • NHS England

  • NHS Greater Huddersfield Clinical Commissioning Group

  • NHS Wigan Borough Clinical Commissioning Group

  • Welsh Government

IV. Commentator organisations (did not provide written evidence and without the right of appeal):

  • Department of Health, Social Services and Public Safety for Northern Ireland

  • Healthcare Improvement Scotland

  • Institute of Cancer Research

  • National Cancer Research Institute

  • Kleijnen Systematic Reviews Ltd

  • National Institute for Health Research Health Technology Assessment Programme

  • National Collaborating Centre for Cancer

C. The following individuals were selected from clinical expert and patient expert nominations from the consultees and commentators. They gave their expert personal view on ramucirumab for treating advanced gastric cancer or gastro–oesophageal junction adenocarcinoma after chemotherapy by attending the initial Committee discussion and providing a written statement to the Committee. They were also invited to comment on the ACD.

  • Dr Naureen Starling, Consultant Medical Oncologist, nominated by Royal College of Physicians – clinical expert

  • Dr Wasat Mansoor, Consultant Medical Oncologist, nominated by Eli Lilly – clinical expert

E. Representatives from the following company attended Committee meetings. They contributed only when asked by the Committee chair to clarify specific issues and comment on factual accuracy.

  • Eli Lilly and Company

ISBN: 978-1-4731-1642-9